



DIASORIN AND PRECISION SYSTEM SCIENCE CO., LTD SIGN AN AGREEMENT TO DEVELOP A MOLECULAR DIAGNOSTIC ANALYZER FOR LAMP ASSAYS.

Saluggia May 6, 2011 - DiaSorin S.p.A., a global leader in the immunodiagnostics market, is glad to announce that Biotrin International Ltd (“Biotrin”), its fully owned Irish subsidiary, has signed an agreement with Precision System Science Co. Ltd of Japan. for the development of a Nucleic Acid Test (NAT) analyser.

Precision System Science Co., Ltd. (“PSS”) is a Japanese leading global provider of laboratory instruments for nucleic acid extraction and amplification and has several years of experience in the development and production for third parties of automated instruments in the field of molecular diagnostic. According to this agreement, PSS, will develop the first generation analyzer to be used in conjunction with a panel of Nucleic Acid Tests in the clinical area of Infectious Disease which are in development at Biotrin using the LAMP technology.

Since July 2009, Biotrin is the DiaSorin centre for the development and manufacture of molecular diagnostics products using the LAMP (Loop Mediated Isothermal Amplification) technology, licensed from Eiken Chemical Company Ltd in 2008. The first panel of applications will be in the field of infectious disease and onco-haematology and will complement DiaSorin’s current extensive Liaison product offering in the field of



immunodiagnostics. Commercial launch is expected to happen in the second half of next year.

“This agreement , Carlo Rosa - DiaSorin CEO - said, is consistent with DiaSorin’s strategy to enter the rapidly developing market of molecular diagnostics in specialty clinical areas where DiaSorin can leverage on its existing strong presence, brand recognition and customer base.”

About DiaSorin

DiaSorin S.p.A., an international player in the market for in vitro diagnostics, develops, produces and markets reagent kits for clinical laboratory diagnostics. The DiaSorin Group is comprised of 23 companies based in Europe, North, Central and South America, Africa and Asia. It has about 1,500 employees, including more than 110 research and development specialists, and operates six manufacturing and research facilities in Saluggia (Vercelli, Italy), Dietzenbach (Germany), Stillwater (USA), Dublin (Ireland), Dartford (UK) and Johannesburg (SA). The last two were part of the Murex business operations, recently acquired from the Abbott Group. Thanks to its direct sales organization and an international network of over 80 independent distributors, the Group is present in more than 60 countries, offering a broad array of high quality products that includes comprehensive lines for each of the clinical segments in which the Group operates: infectious and viral diseases, management of bone and calcium related diseases, thyroid pathologies, oncology and fertility testing.

For additional information, please visit our website: www.DiaSorin.it

Contacts:

Investor Relations Director

Laura Villa

DiaSorin S.p.A.

laura.villa@DiaSorin.it

+39 02 9647 4567

+39 348 15 11 542

Press Office

Carolina Mailander

c.mailander@mailander.it

+39 335 655 56 51

Bruno Caprioli

caprioli@mailander.it

+39 335 590 14 02